Britian has jumped the gun on gene editing
By Donna Dickenson,
Telegraph [UK]
| 02. 02. 2016
Untitled Document
For the first time Britain’s Human Fertilisation and Embryology Authority (HFEA) has granted researchers permission to use a new “gene editing” technique called Crispr/Cas9 to modify human embryos. This is despite a global summit held last December by the National Academies of Science in Washington which warned that, when it comes to this powerful new technique, no nation should go it alone. Other countries such as the United States are just as advanced as Britain in gene editing – indeed, the techniques authorised by HFEA were partly developed in America. But these nations are, rightly, being more cautious in using it.
Why? Their objections do not rest on religion or Luddite opposition to new technology. And it is not gene editing per se – they have fewer concerns about the technique’s use to correct genetic problems in individual living patients. But around the world, expert scientists and bioethicists are worried about its use to modify human embryos. If such embryos are reimplanted in the womb and born, genetic modifications would not be confined to them, but passed down...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...